Premier Heart's MCG system has proven its
ability to detect local or global ischemia in
multiple independently reviewed clinical
trials

Premier Heart's MCG system is founded on the principles of
evidence-based medicine. As such, we believe that the best way of
demonstrating the accuracy and capabilities of our technogy is through
well designed double-blind clinical trials coupled with ongoing
analysis and review of our system's performance in daily clinical
practice.

This page presents an overview of our peer-reviewed clinical trial
results. It includes summary data for each trial as well as electronic
copies of the peer-reviewed articles detailing the methods used in
each study.

If you have questions or would like more information on any of the
trials listed below please feel free to
contact us.

Summary Data: Clinical Trials 2000—2004

This summary includes statistical information from our
clinical trials between 2000 and 2004, representing a sample
of over 1,000 patients in three major geographic regions
(North America, Europe and Asia).

All studies in this group were performed in accordance with
Premier Heart's Westchester Study Protocol, utilizing
standard double-blind testing and independent verification
of results.

Siegburg Heart Center — Siegburg, Germany
Two studies were performed at the Siegburg heart
center in Siegburg, Germany, evaluating MCG in patient
populations with and without a history of revascularization.

This study was conducted across four centers in Asia
with a sample of 189 patients (including patients
with and without a history of prior revascularization).
This study yielded a sensitivity of 94.8%
(specificity 86.6%, positive predictive value 78.4%,
negative predictive value 97.1%).